Časopisi po područjima
Politike i razmjena
Novelties in immunotherapy of esophageal and stomach cancer
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia; Osijek University School of Medicine, Osijek, Croatia
Puni tekst: engleski, pdf (153 KB)
APA 6th Edition
Bišof, V. (2017). Novelties in immunotherapy of esophageal and stomach cancer. Libri Oncologici, 45 (2-3), 65-68. Preuzeto s https://hrcak.srce.hr/192191
MLA 8th Edition
Bišof, Vesna. "Novelties in immunotherapy of esophageal and stomach cancer." Libri Oncologici, vol. 45, br. 2-3, 2017, str. 65-68. https://hrcak.srce.hr/192191. Citirano 19.06.2018.
Chicago 17th Edition
Bišof, Vesna. "Novelties in immunotherapy of esophageal and stomach cancer." Libri Oncologici 45, br. 2-3 (2017): 65-68. https://hrcak.srce.hr/192191
A high frequency of somatic mutations has been detected in stomach and esophageal cancers which makes them a possible suitable target for the application of immunotherapy. Contemporary immunotherapeutic approaches rely on monoclonal antibodies that inhibit immune checkpoints. The results of early clinical studies are promising, while only a few phase III studies have published their results so far. A particulary promising treatment strategy is the combination of checkpoint inhibitors with other treatment modalities, such as chemotherapy, targeted therapy, radiotherapy or T cells agonists.
esophageal cancer; gastric cancer; checkpoint inhibitors; immunotherapy
Hrčak ID: 192191
Registracija novih korisnika
Zaboravili ste lozinku?